Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2020-12-17 Regulatory Filings
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a press release dated December 17, 2020, but the document itself is short (1394 characters) and primarily serves as a regulatory filing to report information to the SEC. There is no detailed financial data, management discussion, or comprehensive report content. According to the rules, Form 6-K filings are generally classified under Regulatory Filings (RNS) as they are miscellaneous filings that do not fit other specific categories and often include press releases or other announcements. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-12-17 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo Biopharma Group PLC, with the SEC. It includes a press release dated December 15, 2020, but the document itself is short (1394 characters) and primarily serves as a report submission rather than containing detailed financial data or substantive report content. Form 6-K filings are typically used for current reports by foreign private issuers and often include press releases or other announcements. Given the short length and nature of the document, it is best classified as a Regulatory Filing (RNS) rather than a full report like an Annual Report or Interim Report.
2020-12-15 English
AIM Delisting
Regulatory Filings Classification · 98% confidence The document is an official regulatory announcement (RNS) from Mereo BioPharma regarding the delisting of its shares from the AIM exchange and updates on financing/warrant instruments. While it mentions delisting, it is a general regulatory announcement provided via the London Stock Exchange's RNS service. Since it covers multiple topics (delisting, financing, and warrant issuance) and is distributed as a standard regulatory news service filing, 'RNS' is the most appropriate classification.
2020-12-15 English
Key Dates for AIM Delisting
Delisting Announcement Classification · 98% confidence The document is an official announcement from Mereo BioPharma regarding the upcoming delisting of its shares from the AIM exchange. It provides specific dates, deadlines for share conversion, and procedural information for shareholders. While it mentions a delisting, it is an announcement of the process rather than the final legal notice of removal, and it fits the criteria for a regulatory announcement regarding corporate structure changes.
2020-11-30 English
Mereo appoints Suba Krishnan
Regulatory Filings Classification · 98% confidence The document is a press release announcing the appointment of a new Senior Vice President of Clinical Development at Mereo BioPharma. It is distributed via the RNS (Regulatory News Service) platform. Since it details a change in senior management, it falls under the 'Board/Management Information' category.
2020-11-23 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a press release dated November 16, 2020, but the text provided is very short (1356 characters) and does not contain detailed financial data or substantive report content. It is primarily an announcement filing with an exhibit index referencing a press release. According to the rules, such filings that are short and serve as announcements or submissions of reports without the full report content should be classified as Regulatory Filings (RNS).
2020-11-16 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.